Explore the vast range of titles available.

It is estimated that in utero SARS-CoV-2 infection is rare. However, few studies have systematically assessed for IgA and IgM antibodies indicating potential in utero response to SARS-CoV-2 infection using multi-isotype serology, and no studies have assessed in utero infection markers in relation to circulating variants. Between October 21, 2021 and February 15, 2023, remnant cord blood samples (CBS) from neonates born at a single hospital in Los Angeles, were systematically tested for serological markers suggesting in utero infection. SARS-CoV-2 specific fetal IgA and/or IgM antibodies were detected in 28.7% (298/1038 CBS, 95% CI: 26.0, 31.6), higher than previous in utero infection estimates that used only PCR and/or IgM. Importantly, the probability of detecting markers of in utero infection varied by month ( P -value = 0.0144). The prevalence of fetal IgA/IgM varied with the emergence of new variants, increasing during the BA.1 wave with a peak in February 2022 at 36% (18/50, 95% CI: 22.7-49.3) and again during the BA.4/5 wave, with a peak at 48.8% in September 2022 (39/80, 95% CI 37.8-59.7), suggesting variant-related fluctuations. These data suggest it may be useful to identify SARS-Cov-2 in utero exposure at birth so these newborns may be more closely followed for adverse clinical outcomes. Here the authors test 1405 remnant cord blood samples and find SARS-CoV-2 specific fetal IgA and/or IgM antibodies in 28.7% of samples, showing in utero exposure to SARS-CoV-2. The prevalence of fetal IgA/IgM varies with SARS-CoV-2 variant.

Background This study is a long-term follow-up of individuals exposed to polybrominated biphenyls (PBBs). Widespread contamination of PBBs began in 1973 in Michigan when PBBs entered the food chain. PBBs are synthetic chemicals that were once used in industrial products. Their production in the United States ended following this incident. PBBs and other brominated flame retardants belong to a class of persistent organic pollutants that have been shown to affect human health. We conducted this study to investigate whether PBB exposure was associated with all-cause or cause-specific mortality risk. Methods We included cohort data from 1976 (when the study began) and linked to National Death Index data obtained through the early release of 2021. Serum PBB concentrations were measured at enrollment in the study. We used survival analysis to estimate sex-specific hazard ratios (HR) and 95% confidence intervals (CI), adjusting for age and other important risk factors. The mortality study included 3,954 individuals. Results In age-stratified analyses, higher PBB exposure was not associated with all-cause mortality risk in males or females. In cause-specific analyses conducted in the 16 or older group, we found no association between PBB exposure and circulatory system disease mortality. For all-cancer mortality, we found higher PBB exposure associated with increased risk of mortality in females (HR: 1.50, 95% CI: 1.02–2.22), which was inversed in males (HR: 0.68, 95% CI: 0.46–1.01). BMI appeared to modify the association between PBB exposure and all-cause mortality risk in males and all-cancer mortality risk in males and females. Conclusions This comprehensive study found that the association between PBB exposure and cancer mortality risk varied by sex. Further research is needed to understand these sex-specific differences.

Circulating exosomes are promising biomarker source in various diseases. Exosomal constituents can stably exist in the circulating plasma and serum thus making them ideal biomarkers for a number of clinical applications. Exosomes can also mediate the occurrence of many types of diseases, including distal cancerous metastasis and tumour enlargement, through encapsulated proteins or RNAs, which regulate interactions among tissues. While performing these actions, exosomes show tissue specificity. However, the mechanism for such selection is not clear. For non-small cell lung cancer (NSCLC), molecular diagnostic markers and mechanisms of exosome-mediated tumour metastasis are not well understood. Therefore, in this study, we characterized LLC exosomal proteins and mRNAs by analysing their molecular profiles, laying a foundation for exploring diagnostic markers of lung cancer. Furthermore, the interactions between exosomal membrane proteins and their target proteins were analysed and revealed a possible tissue propensity of LLC cell-derived exosomes. These findings provide a theoretical basis for studying exosome-mediated tissue targeting and distal lung cancer metastasis.